Cell MedX Corp Share Price OTC Bulletin Board
Equities
US15115X1072
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-15 | Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
03-12 | Cell MedX Corp. announced that it has received $0.075 million in funding | CI |
Sales 2022 | 0.01 0.48 | Sales 2023 | 0 0.22 | Capitalization | 6.29K 502K |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 1,135,153,669 x |
Net Debt 2022 | 592K 47.3M | Net Debt 2023 | 903K 72.08M | EV / Sales 2023 | 329,116,944 x |
P/E ratio 2022 |
-9.01
x | P/E ratio 2023 |
-0.01
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20.34% |
Managers | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12-11 |
Yanika Silina
DFI | Director of Finance/CFO | 45 | 23/11/14 |
George Adams
CHM | Chairman | 76 | 22/03/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12-11 |
Dwayne Yaretz
BRD | Director/Board Member | 63 | 26/04/22 |
Joao da Costa
BRD | Director/Board Member | 59 | 07/06/20 |
1st Jan change | Capi. | |
---|---|---|
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |